Fig. 2
From: Psychedelic microdosing benefits and challenges: an empirical codebook
![Fig. 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12954-019-0308-4/MediaObjects/12954_2019_308_Fig2_HTML.png)
Percentage of microdosers endorsing improved behaviours and reductions in substance-use. Prevalence rate should be used for hypothesis generation as these data indicate reported outcomes, not confirmed effects. *Note: Anxiety refers to improvements to anxiety-related experiences, not to increased experience of anxiety